Antineoplastics

1
Reactions 395 - 4 Apr 1992 S Antineoplastics Mucositis: clinical study Grade 3 or 4 mucositis occurred in 11/25 cycles of antineoplastic therapy administered to 18 patients with nonsmall cell lung cancer. The antineoplastic regimen consisted of vinorelbine, fluorouracil, calcium folinate leucovorin calcium and cisplatin. In 10/22 cycles grade 3 or 4 neutropenia was also noted. Three patients with severe mucositis and neutropenia died of sepsis. As toxicity was unacceptable, the study was stopped. The authors suggested that vinorelbine significantly potentiated fluorouracil-induced mucosal toxicity in this study, and that this effect was more marked in the presence of calcium folinate Monnet I, et al. Severe mucositis after chemotherapy vinorelbine, 5-fluorouracil, leucovorin and cisplatin. European Journal of Cancer 27: 1716-1717, Dec 1991 - France 800124282 1 Reactions 4 Apr 1992 No. 395 0114-9954/10/0395-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Transcript of Antineoplastics

Page 1: Antineoplastics

Reactions 395 - 4 Apr 1992

SAntineoplastics

Mucositis: clinical studyGrade 3 or 4 mucositis occurred in 11/25 cycles of

antineoplastic therapy administered to 18 patients withnonsmall cell lung cancer. The antineoplastic regimenconsisted of vinorelbine, fluorouracil, calcium folinateleucovorin calcium and cisplatin.

In 10/22 cycles grade 3 or 4 neutropenia was also noted.Three patients with severe mucositis and neutropenia died ofsepsis. As toxicity was unacceptable, the study was stopped.

The authors suggested that vinorelbine significantlypotentiated fluorouracil-induced mucosal toxicity in this study,and that this effect was more marked in the presence ofcalcium folinateMonnet I, et al. Severe mucositis after chemotherapy vinorelbine, 5-fluorouracil,leucovorin and cisplatin. European Journal of Cancer 27: 1716-1717, Dec 1991 -France 800124282

1

Reactions 4 Apr 1992 No. 3950114-9954/10/0395-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved